Heron's pain candidate meets in Phase IIb ahead of NDA

Heron Therapeutics Inc. (NASDAQ:HRTX) reported that HTX-011 met the primary endpoint in a pair of Phase IIb trials to treat postoperative pain. Heron intends to submit an NDA to FDA next half for the candidate. FDA also granted breakthrough therapy designation to HTX-011.

HTX-011 is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam using Heron’s Biochronomer polymer-based drug delivery platform...